MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 29.72M | 31.23M | 32.31M | 32.98M | 31.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.72M | 31.23M | 32.31M | 32.98M | 31.85M |
| Cost of Revenue | 19.65M | 21.49M | 21.73M | 23.12M | 21.48M |
| Gross Profit | 10.08M | 9.73M | 10.58M | 9.86M | 10.37M |
| SG&A Expenses | 12.55M | 14.99M | 15.51M | 15.47M | 16.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 315.10K | 336.20K | 221.90K | 83.00K | 111.50K |
| Total Operating Expenses | 32.66M | 36.94M | 37.61M | 38.84M | 38.02M |
| Operating Income | -2.94M | -5.71M | -5.30M | -5.86M | -6.17M |
| Income Before Tax | -3.59M | -6.32M | -5.96M | -5.78M | -6.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.59 | -6.32 | -5.96 | -5.78 | -6.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.59M | -6.32M | -5.96M | -5.78M | -6.26M |
| EBIT | -2.94M | -5.71M | -5.30M | -5.86M | -6.17M |
| EBITDA | -1.83M | -4.57M | -4.13M | -4.61M | -4.84M |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.69B | 1.68B | 1.67B | 1.66B | 1.65B |
| Average Diluted Shares Outstanding | 1.69B | 1.68B | 1.67B | 1.66B | 1.65B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |